NCT06293014View on ClinicalTrials.gov

TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

February 23, 2024

Primary Completion Date

October 15, 2025

Study Completion Date

November 28, 2026

Conditions
Colorectal Cancer
Interventions
DRUG

TAS-102+bevacizumab

TAS-102 35mg/m2, PO, D1-5, repeated every 14 days; Bevacizumab 5mg/kg, IV, D1, repeated every 14 days; Q4w.

DRUG

Standard chemotherapy+bevacizumab

Standard chemotherapy (chemotherapy regimen based on investigator's choice, including FOLFIRI, FOLFOX, or CAPEOX); Bevacizumab

Trial Locations (1)

450008

RECRUITING

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV